🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Generalized Myasthenia Gravis

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) NCT07647510Phase 34 sites📍 Pasadena📍 Boca Raton📍 Fayetteville Dianthus Therapeutics · Tests: Claseprubart, Placebo, Claseprubart, Placebo A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) NCT06987539Phase 214 sites📍 Chicago📍 Philadelphia📍 Austin Amgen · Tests: Inebilizumab Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) NCT04202341n/a51 sites📍 Birmingham📍 Scottsdale📍 Fresno Alexion Pharmaceuticals, Inc. GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103) NCT07058298EARLY Phase 11 site📍 Wuhan Daishi Tian · Tests: GC012F injection Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis NCT04833894Phase 2, Phase 325 sites📍 Chicago📍 Chapel Hill📍 Charlottesville argenx · Tests: Efgartigimod IV Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) NCT07596784Phase 310 sites📍 Beijing📍 Changchun📍 Fuzhou Alexion Pharmaceuticals, Inc. · Tests: Ravulizumab Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis NCT05067348Phase 26 sites📍 Beijing📍 Changsha📍 Xi'an Tang-Du Hospital · Tests: Tocilizumab Injectable Product ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis NCT07673627Phase 28 sites📍 Carlsbad📍 Miami📍 Las Vegas argenx · Tests: Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis NCT07246564Phase 412 sites📍 Beijing📍 Changchun📍 Changsha UCB Biopharma SRL · Tests: Rozanolixizumab Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research NCT04806620n/a1 site📍 Delafield Brain Inflammation Collaborative Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis NCT07411963n/a8 sites📍 Nice📍 Bron📍 Garches Centre Hospitalier Universitaire de Nice · Tests: early use of Ravulizumab A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis NCT06055959Phase 2, Phase 39 sites📍 Chicago📍 Denton📍 Milan UCB Biopharma SRL · Tests: Zilucoplan Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod NCT07072988Phase 49 sites📍 Nice📍 Créteil📍 Garches Centre Hospitalier Universitaire de Nice · Tests: Efgartigimod KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis NCT06193889Phase 2, Phase 322 sites📍 Los Angeles📍 Orange📍 Palo Alto Kyverna Therapeutics · Tests: Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101 A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis NCT06688435Phase 11 site📍 Jinan CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Tests: SYS6020 injection, SYS6020 injection, SYS6020 injection Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis NCT06909253n/a11 sites📍 Bydgoszcz📍 Gdansk📍 Katowice AstraZeneca · Tests: Ravulizumab Zilucoplan for Severe gMG Exacerbations NCT07215949Phase 33 sites📍 Tampa📍 Kansas City📍 Columbus Miriam Freimer · Tests: Zilucoplan® PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis NCT06607627Phase 313 sites📍 Washington D.C.📍 Norfolk📍 Joinville Alexion Pharmaceuticals, Inc. · Tests: Gefurulimab PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis NCT07717281n/a1 site📍 Milan Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis NCT06371040Phase 11 site📍 Xi'an Ting Chang, MD · Tests: CD19-BCMA Targeted CAR-T Dose 1, CD19-BCMA Targeted CAR-T Dose 2, CD19-BCMA Targeted CAR-T Dose 2 Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) NCT07215650Phase 110 sites📍 Fuzhou📍 Guangzhou📍 Guangzhou Candid Therapeutics · Tests: Cizutamig A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis NCT04951622Phase 3112 sites📍 Paradise Valley📍 Scottsdale📍 Los Angeles Janssen Research & Development, LLC · Tests: Nipocalimab, Placebo, Nipocalimab SC-LIV RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis NCT06359041Phase 1, Phase 217 sites📍 Orange📍 Sacramento📍 San Francisco Cabaletta Bio · Tests: CABA-201, CABA-201 Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) NCT06463587Phase 3154 sites📍 Phoenix📍 Longmont📍 Farmington Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of … · Tests: Placebo, Cladribine Low Dose, Cladribine High Dose ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis NCT07294170n/a37 sites📍 Carlsbad📍 Miami📍 Miami argenx · Tests: Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS Myasthenia Gravis Foundation of America Global MG Patient Registry NCT06617741n/a1 site📍 Westborough Myasthenia Gravis Foundation of America A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) NCT06909214Phase 418 sites📍 La Jolla📍 Rancho Mirage📍 Boca Raton argenx · Tests: Efgartigimod PH20 SC A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab NCT07221838Phase 412 sites📍 Chicago📍 Schaumburg📍 Neptune City Alexion Pharmaceuticals, Inc. · Tests: Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis NCT07250750Phase 1, Phase 225 sites📍 Altamonte Springs📍 Boca Raton📍 Naples ImmunAbs Inc. · Tests: IM-101 Part A, Placebo Part A, IM-101 Part B, Placebo Part B
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy